Welcome to our dedicated page for China Pharma SEC filings (Ticker: CPHI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The China Pharma Holdings, Inc. (CPHI) SEC filings page on Stock Titan provides access to the company’s U.S. regulatory disclosures, including current reports, proxy materials, and registration-related documents. As a Nevada corporation with common stock listed on the NYSE American under the symbol CPHI, China Pharma files reports that describe its governance decisions, capital structure changes, and key contractual arrangements.
Form 8-K filings for China Pharma include disclosures about annual stockholders’ meetings, the election of independent directors, and stockholder votes to authorize reverse stock splits at ratios of up to 1:20. These reports also detail board decisions to implement specific reverse stock split ratios and explain how such actions affect outstanding common stock. Other 8-K filings describe material definitive agreements, such as technology transfer agreements entered into by the company’s wholly owned subsidiary, Hainan Helpson Medical & Biotechnology Co., Ltd., for invention patents covering ipragliflozin tablets and captopril microcapsules. In these agreements, transfer prices are to be paid in restricted shares of China Pharma’s common stock issued under Regulation S.
Proxy materials, such as the company’s definitive proxy statement on Schedule 14A, outline matters submitted to stockholders, including the election of independent directors, authorization of reverse stock splits, and amendments to long-term incentive plans. Registration-related filings, including the shelf registration statement on Form S-3 referenced in company news, support offerings like at-the-market equity financings.
On Stock Titan, these filings are paired with AI-powered summaries that highlight the main points of lengthy documents, helping users understand topics such as equity issuance, reverse stock split mechanics, technology acquisitions, and stockholder voting outcomes. Real-time updates from EDGAR, along with access to insider-related forms and periodic reports when filed, allow investors and researchers to review China Pharma’s regulatory history and ongoing disclosure obligations in a structured way.
China Pharma Holdings, Inc. reported that its wholly owned subsidiary Hainan Helpson Medical & Biotechnology entered a Technology Transfer Agreement to acquire ownership of an invention patent for a Topiroxostat nanoemulsion and its preparation method from Xiaoyun Chen.
The transfer price is $8.82 million, to be paid in Company common stock at $0.70 per share, implying issuance of 12,600,000 restricted shares. Closing is expected by February 20, 2026. The shares will be issued in an offshore transaction to a non-U.S. person under Regulation S, without registration under the Securities Act.
China Pharma Holdings, Inc. reported results from its annual stockholders’ meeting for the fiscal year ended December 31, 2024. A total of 3,501,046 common shares, representing about 69.71% of outstanding shares as of the November 3, 2025 record date, were present in person or by proxy, providing a sufficient quorum.
Stockholders elected three independent directors—Gene Michael Bennett, Yingwen Zhang, and Baowen Dong—each receiving 3,500,416 to 3,500,418 votes for, with 628 to 630 votes withheld. Stockholders also approved an amendment to the Articles of Incorporation authorizing a reverse stock split at a ratio of up to 1-for-20 for the Company’s $0.001 par value common stock, with the Board retaining discretion over if and when to implement it. In addition, Amendment No. 3 to the Company’s Amended and Restated 2010 Long-Term Incentive Plan was approved, with 3,500,258 votes for, 774 against, and 14 abstentions.
China Pharma Holdings, Inc. reports that its wholly owned subsidiary, Hainan Helpson Medical & Biotechnology Co., Ltd, entered into a Technology Transfer Agreement with Juan Zhang to acquire an invention patent covering Ipragliflozin tablets and their preparation method. The agreed transfer price is $9.8 million, to be paid in the company’s common stock at $1.40 per share.
To satisfy this consideration, the company is to issue 7,000,000 restricted shares of common stock. These shares will be offered and issued to a non-U.S. person in an offshore transaction relying on Regulation S, meaning they will not be registered under the U.S. Securities Act or state securities laws.
China Pharma Holdings, Inc. reports that its wholly owned subsidiary, Hainan Helpson Medical & Biotechnology Co., Ltd, has entered into a Technology Transfer Agreement to acquire an invention patent for a Captopril microcapsule and its preparation method from an individual transferor. As consideration, the company values the transaction at
China Pharma Holdings (CPHI) called its Annual Meeting for December 30, 2025 to vote on three items: re‑elect three independent directors, authorize a reverse stock split of up to 1:20 at the Board’s discretion, and approve Amendment No. 3 to the Amended and Restated 2010 Long‑Term Incentive Plan to increase the share reserve by 500,000 shares (from 69,600 to 569,600).
The reverse split proposal is positioned as a tool to address potential NYSE American “low selling price” concerns; the Board notes prior reverse splits of 1‑for‑5 and 1‑for‑10 in 2024 and 2025. Fractional shares would be rounded up to a full share. Shares outstanding were 5,022,002 as of November 3, 2025, the record date. The proxy outlines standard voting mechanics, quorum (one‑third of outstanding), and recommends voting “FOR” all proposals. The filing also details 2024 audit fees of $125,000 and executive/director compensation, including CEO 2024 salary of $300,000 and outstanding restricted stock of 48,200 under the plan.
China Pharma Holdings (CPHI) reported Q3 2025 results showing continued losses amid tight liquidity. Revenue was $756,217, with a gross loss of $59,654 and net loss of $651,482 (loss per share $0.17). For the nine months, revenue was $2,918,271 and net loss was $1,965,421.
The company flagged substantial doubt about its ability to continue as a going concern. Cash and equivalents were $267,625 as of September 30, 2025, and current liabilities exceeded current assets by $4.3 million. Borrowings from the Chair/CEO totaled $1,413,340, supporting working capital.
Results improved year over year on lower depreciation and reduced inventory obsolescence, narrowing gross loss and operating loss. The company wrote off $13.7 million of long‑aged receivables in August 2025, sharply reducing the allowance. It also issued 1,760,000 shares for a patent asset valued at $2.446 million. A 1‑for‑10 reverse split took effect April 15, 2025; shares outstanding were 5,022,002 as of November 10, 2025.